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Abstract
The metabolic syndrome, a cluster of metabolic derangements that include obesity, glucose
intolerance, dyslipidemia and hypertension, is a major risk factor for cardiovascular disease.
Insulin resistance has been proposed to be the common feature that links obesity to the metabolic
syndrome, but the mechanism remains obscure. Although the excess content of triacylglycerol in
muscle and liver is highly associated with insulin resistance in these tissues, triacylglycerol itself
is not causal but merely a marker. Thus, attention has turned to the accumulation of cellular lipids
known to have signaling roles. This review will discuss recent progress in understanding how
glycerolipids and related lipid intermediates may impair insulin signaling.
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Obesity, lipids & insulin resistance
By 2020, more than 300 million people worldwide will be affected by the cardiometabolic
risk factors that constitute the metabolic syndrome, obesity, glucose intolerance,
dyslipidemia and hypertension [1,2]. The most accepted unifying theory to explain the
pathophysiology of the metabolic syndrome is the presence of insulin resistance [3]. In
insulin resistance, insulin becomes less effective at lowering blood glucose through
diminished glucose uptake in peripheral tissues (muscle and adipose) and failure to suppress
hepatic gluconeogenesis [4,5].
Hypotheses have been proposed to explain the molecular mechanism of insulin resistance
including:
• A mismatch between fatty acid oxidation and the tricarboxylic acid cycle [6,7];
• Inflammatory cytokines that cause endoplasmic reticulum (ER) stress and
mitochondrial dysfunction [8];
• The production of signaling lipids, including ceramide, acyl-coenzyme As (acyl-
CoAs), diacylglycerol (DAG) and phosphatidic acid (PA) [9,10].
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In this review, we will focus on recent studies of lipid intermediates related to, or derived
from, triacylglycerol (TAG) biosynthesis and the mechanisms by which these lipids are
thought to impair insulin signaling.
TAG synthesis & its association with insulin resistance
Insulin resistance is strongly associated with excess TAG stores in multiple tissues,
suggesting that insulin signaling might be diminished by the accumulation of specific lipids
[11]. TAG biosynthesis begins with the activation of long-chain fatty acids by members of a
family of acyl-CoA synthetases. Their long-chain acyl-CoA products are then esterified to
glycerol-3-phosphate by glycerol-3-phosphate acyltransferase (GPAT) to form
lysophosphatidic acid (LPA) [12]. This initial esterification step, catalyzed by four GPAT
isoforms, is the rate-limiting step in TAG synthesis [12]. A second long-chain acyl-CoA is
esterified to the resultant LPA product by one of at least three isoforms of acyl-GPAT
(AGPAT; also called lysophosphatidic acid acyltransferase) to form PA, which is then
hydrolyzed by one of three isoforms of PA phosphohydrolase (lipin) to form DAG. One of
two isoforms of DAG acyltransferase esterifies the DAG with a third long-chain acyl-CoA
to produce TAG.
Many studies have demonstrated the association between lipid accumulation and insulin
resistance; however, as a neutral lipid sequestered in lipid droplets, TAG itself is unlikely to
be a signaling molecule. Instead, an increasing body of evidence suggests that one or more
of the lipid intermediates produced during TAG synthesis interfere with the intracellular
insulin signaling pathway and contribute to the development of insulin resistance (Figure 1).
Lysophosphatidic acid
Indirect evidence that elevated LPA causes insulin resistance comes from rodent models in
which GPAT was genetically manipulated. When GPAT1 was overexpressed in rat liver,
LPA content increased approximately fourfold and a hyperinsulinemic–euglycemic clamp
study demonstrated hepatic insulin resistance [13]. Conversely, when mice lacking GPAT1
(Gpat1−/−) were fed a high-fat diet, hepatic LPA content was reduced and the mice retained
hepatic insulin sensitivity [14]. In addition to its production by de novo synthesis, LPA can
also be generated by the hydrolysis of lysophosphatidylcholine by lysophospholipase D
[15]. However, LPA generated from phospholipids has not been linked to insulin signaling.
In addition to effects mediated by plasma membrane-associated LPA receptors, LPA
synthesized by GPAT1 can act as a ligand for the nuclear receptor PPARγ [16,17], whose
activation improves insulin sensitivity in rodents and humans [18]. Since the overexpression
of hepatic GPAT1 causes rats to become insulin resistant [13], it is unlikely that LPA
derived from the de novo synthesis pathway activates PPARγ. However, LPA derived from
other pathways could activate PPARγ and lead to improved insulin sensitivity.
Phosphatidic acid
PA is produced by several pathways, including the hydrolysis of membrane phospholipids
by phospholipase D (PLD), the phosphorylation of DAG by DAG kinase (DGK) and the
esterification of LPA by AGPAT (Figure 1). The first evidence to suggest that PA regulates
insulin sensitivity came from a study in which PLD-mediated production of PA activated the
mTORC1 protein complex and its downstream targets [19]. When exogenous PA was added
to cultured HEK293 cells, S6 kinase (S6K)-1 was activated in an mTORC1-dependent
manner, and mTORC1 activation by serum was dependent on PLD1 [19]. Since the
activation of mTORC1 and S6K1 enhances IRS-1 phosphorylation on Ser307, 632 and
636/639 residues [20,21], PA derived via PLD could cause insulin resistance by stimulating
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mTORC1–S6K1 signaling to increase serine phosphorylation of IRS-1. In contrast to the
inhibition of insulin signaling by mTORC1, mTORC2 [22] enhances insulin signaling by
phosphorylating and activating Akt at Ser473 [23]. Surprisingly, the PA derived via PLD
action stabilizes both mTORC1 and mTORC2 complexes [24]. This stabilization suggests
paradoxical outcomes with both enhanced and inhibited insulin signaling. However, the
hypothesized effect of PLD-derived PA in regulating insulin signaling has not been directly
investigated, and studies that relate PA content or PA treatment and mTOR activity are
primarily associative; direct in vivo evidence for altered insulin signaling is lacking.
A second pathway that produces PA is the phosphorylation of DAG by one of ten DGK
isoforms [25]. DGK manipulates the cellular content of DAG and PA simultaneously by
phosphorylating DAG to form PA [26]. Although one study showed an association between
DGKδ inhibition and insulin resistance in skeletal muscle [27], this study examined changes
in DAG, but not PA. It is not known whether a DGK-mediated increase in PA content leads
to impaired insulin signaling.
The third pathway of PA generation is the esterification of LPA by AGPAT. We have
shown that overexpressing GPAT1 or AGPAT2 blocks insulin’s ability to suppress hepatic
glucose production [28]. In our study, overexpressing GPAT1 or AGPAT2 increased the
cellular content of 16:0-containing PA approximately 2.2-fold. Of the various LPA, DAG
and PA species that were tested, only di-16:0 PA disassociated the mTOR–rictor complex
and inhibited mTORC2 activity. Our results showed that in hepatocytes that overexpressed
GPAT1, the absent phosphorylation of Akt at Ser473 and Thr308 diminished insulin
signaling. This study provided direct evidence that a particular PA species inhibits insulin
signaling.
PA appears to stabilize mTORC1 by interacting with the FKBP12–rapamycin-binding
domain of mTOR [19]. PA has also been reported to activate and stabilize mTORC2 [24],
probably by the same mechanism. These stabilization results focused on PA derived from
the hydrolysis of membrane phospholipids by PLD. By contrast, PA produced via the
glycerolipid synthetic pathway disrupts the mTORC2 complex [28]. It is unclear how PA
originating from different sources can engender opposite effects on mTOR complex
integrity. PA derived from both glycerolipid synthesis and from PLD-mediated phospholipid
hydrolysis should be able to interact with the same FKBP12–rapamycin-binding domain of
mTOR. Opposite effects on function may be due to each pathway of PA producing species
that vary in their fatty acid composition. Although it is not known which PA species
predominate in the PLD-derived PA that interacts with mTORC1 and mTORC2, the
molecular species probably depend on the agent used to activate PLD, the cell type
employed, and the phospholipid species that is hydrolyzed [29–32]. In contrast to the PA
produced by overexpressing GPAT1, PLD-derived PA species are unlikely to contain
predominately 16:0 fatty acids. Characterizing the nature of the pools of PA derived from
PLD and from TAG synthesis will be critical to understanding normal and dysfunctional
nutrient lipid signaling, particularly as it relates to nutrient surfeit and insulin resistance.
Although di-16:0 PA derived from GPAT1 overexpression inhibits mTORC2 in vitro [28],
other PA species may inhibit mTORC2 activity in vivo. As it should be more difficult to
dissociate an already formed mTORC2 complex than to prevent the initial association of the
complex, lower concentrations of PA or different species might be effective in vivo.
Diacylglycerol
PKCε is thought to block the insulin signaling pathway by phosphorylating IRS1 at multiple
serine residues [33], either directly or via activation of IKKβ and JNK [34–36]. Since DAG
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activates PKCε, hepatic DAG content is believed to link TAG synthesis and insulin
sensitivity, particularly under conditions of hepatic steatosis [10]. Evidence exists both in
favor of and against DAG as a major regulator of insulin signaling. Favoring DAG
regulation are studies in which changes in GPAT alter DAG production. When GPAT1 is
overexpressed in rat liver, insulin resistance occurs, DAG content increases twofold and
PKCε protein translocates from the cytosol to the membrane [13]. Conversely, in Gpat1−/−
mice fed a high-fat diet, normal hepatic insulin sensitivity is retained, the hepatic DAG
content is 2.5-fold lower than in controls fed a low-fat diet and the ratio of membrane- to
cytosol-associated PKCε protein is reduced [14]. In rats infused with linoleic acid (18:2ω6),
muscle becomes insulin resistant and soleus muscle DAG content increases, together with
increased membrane localization of the PKCε and PKCθ proteins [34]. As with rats, humans
infused with a 20% TAG emulsion (10% safflower and 10% soybean oil) develop increased
skeletal muscle DAG content and PKC (β and δ) activity [37]. Feeding rats a 59%-fat diet
for 3 days causes hepatic insulin resistance [38], which is prevented by antisense
oligonucleotide-mediated PKCε gene knockdown [33]. Although these data demonstrate a
strong association between DAG, activated PKC isoforms and insulin resistance, most of
these studies have reported changes only in the ratio of membrane- and cytosol-associated
PKC isoforms as a proxy for PKC activation, and have not measured PKC activity directly.
Several human studies contradict the idea that excess DAG causes insulin resistance. For
example, a 7-h intralipid infusion reduces insulin sensitivity in skeletal muscle (vastus
lateralis), without changing the content of intramyocellular DAG [39]. Obese women are
more insulin sensitive than obese men during saline or lipid infusion, without differences in
vastus lateralis DAG concentration [40]. Although diabetic and nondiabetic subjects have
similar intramyocellular DAG content, the diabetic patients have higher TAG content [41].
Similarly, the intramuscular DAG content is comparable in obese subjects with or without
impaired glucose tolerance [42]. In normal-weight, endurance-trained athletes, the
myocellular DAG content is twofold higher than in obese, sedentary subjects, but insulin
sensitivity in the latter group is lower [43]. In addition, the muscle DAG content does not
differ in lean insulin-sensitive subjects and obese people with insulin resistance [44].
Cell and animal studies also show that high DAG is not invariably accompanied by insulin
resistance. In human primary myotubes and in mouse skeletal muscle, administration of
ethyl-2-(6-[4-chlorophenoxy]hexyl)-oxirane-2-carboxylate (etomoxir), an inhibitor of
carnitine palmitoyltransferase and fatty acid oxidation, results in improved insulin
sensitivity, despite increased DAG content [45]. Mice deficient in hepatic microsomal TAG
transfer protein have impaired VLDL secretion with hepatic steatosis and high DAG
content, but retain normal insulin sensitivity [46]. Finally, liver-specific overexpression of
DAG acyltransferase in mice results in increased hepatic TAG and DAG content, but,
strikingly, no change in hepatic insulin sensitivity [47,48].
These discrepancies in DAG-mediated insulin resistance may be due to the presence of
distinct DAG species with differing signaling properties [49]. Alternatively, under some
circumstances, the DAG might be sequestered in a nonsignaling pool (e.g., in lipid droplets)
and, thus, not be able to activate PKC.
Cellular DAG content is also regulated by the activity of DGK (Figure 1). In patients with
Type 2 diabetes, the skeletal muscle content of DGKδ protein and DGK activity is reduced
[27]. In addition, in hyperglycemic, insulin-resistant Goto Kakizaki rats, reductions in
DGKδ protein and DGK activity are accompanied by an increased content of DAG in the
muscle [27]. The relationship of other DGK isoforms to insulin resistance has not been
reported.
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When GPAT1 or AGPAT2 is overexpressed in mouse hepatocytes, the content of DAG
species containing palmitate increases 3.4- and 1.7-fold, respectively, and correlates with the
inhibition of mTORC2 activity and the phosphorylation of Akt at Ser473 and Thr308, and of
GSK3α phosphorylation at Ser21. This correlation between cellular DAG content and
mTORC2 activity and downstream signaling suggests that DAG synthesized de novo via the
Kennedy pathway might contribute to hepatic insulin resistance [28]. Although the several
DAG species evaluated did not disrupt the mTOR–rictor complex in vitro [28], hydrophobic
DAG molecules may not be able to access the mTORC2 complex in vitro, which may not
reflect in vivo conditions.
Acyl-CoA & ceramide
Other lipids frequently cited as blunting insulin signaling are acyl-CoAs and ceramide.
Long-chain acyl-CoA synthetases activate long-chain fatty acids to form acyl-CoAs, whose
metabolic fates include entrance into pathways of complex lipid synthesis or mitochondrial
β-oxidation [50,51]. Compared to animals on a control diet, rats fed a high-saturated-fat diet
had 18 and 46% higher total acyl-CoA concentrations in liver and skeletal muscle,
respectively [52]. Similarly, insulin resistance developed together with high skeletal muscle
content of acyl-CoAs in rats fed a 59%-safflower oil diet [53,54] or a 45%-lard diet [55].
These studies provide evidence that long-chain acyl-CoAs may mediate the development of
insulin resistance, either indirectly by increasing DAG, as described above, or by increasing
ceramide, which inhibits hexokinase and diminishes glucose uptake, and which also
activates PKCθ to disrupt the insulin signaling pathway [56,57].
Other studies have reported that intracellular acyl-CoAs accumulate independent of insulin
resistance. For example, mice deficient in either malonyl-CoA decarboxylase [57] or
thioesterase superfamily member 1 [58] are protected from diet-induced insulin resistance,
despite an elevated tissue content of acyl-CoA. Similarly, a deficiency of GPAT1 results in a
1.6-fold increase in the liver content of acyl-CoA, but Gpat1−/− mice are protected from
hepatic insulin resistance induced by a high-safflower oil diet [14]. Taken together, the
studies relating elevated tissue acyl-CoA content and impaired insulin signaling remain
inconclusive.
The evidence that ceramide reduces insulin signaling is better supported [59]. Depending
upon the cell type, ceramide interferes with insulin signaling by two separate mechanisms,
both of which involve Akt translocation to the plasma membrane. In C2C12 myotubes,
ceramide interferes with insulin signaling by enhancing the dephosphorylation of Akt by
PP2A, thereby blocking the movement of Akt to the plasma membrane [60]. In rodent and
human adipocytes, as well as L6 myotubes, ceramide inhibits the translocation of Akt to the
plasma membrane by a mechanism involving the atypical PKC aPKCζ [61]. Ceramide-
activated aPKCζ phosphorylates Akt at Thr34 [61,62], leading to retention of the phosphor-
Akt in caveolin-enriched membranes [63] where it is unresponsive to insulin. It is unclear
why there are differences between the two mechanisms and which mechanism prevails in
vivo. Despite these differences, the common end point of ceramide-disrupted insulin
signaling remains reduced active pAkt at the plasma membrane. In addition to these in vitro
models, evidence from in vivo models supports the role of ceramide in insulin resistance.
Using mice deficient in Toll-like receptor-4, researchers demonstrated that inflammation is
also involved in ceramide-induced insulin resistance [64]. Although plasma ceramide is high
in adolescents with Type 2 diabetes, it is not known whether the ceramide elevation is a
cause or a consequence of diabetes [65]. Consistent with the idea that ceramide mediates
insulin resistance, mice deficient in dihydroceramide desaturase 1, the enzyme that converts
dihydroceramide into ceramide, retain insulin sensitivity after treatment with
dexamethasone. This model is problematic, however, because the null animals have
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additional systemic problems and die by the age of 10 weeks [66]. More conclusive
evidence for the role of ceramide in insulin resistance comes from mice fed a 60%-fat diet
[67]. Both the insulin resistance and doubling of skeletal muscle ceramide that developed by
12 weeks were blocked when myriocin, an inhibitor of ceramide synthesis, was fed
concomitantly.
Subcellular location and accessibility of lipid intermediates
Since the enzymes involved in lipid metabolism are located on or within specific subcellular
organelles, their lipid products vary in concentration in different subcellular compartments.
Cellular compartmentalization of lipids may contribute to the ability of a lipid species to
regulate insulin signaling. For example, different GPAT, AGPAT and DGK isoforms are
located on multiple organelles [12]. PA is water-soluble and should be able to move within
the cytoplasm, so its abundance in different compartments may vary depending on its site of
origin. The PA produced by AGPAT isoforms located at the mitochondrial outer membrane
or the ER [68] may have access to specific downstream pathways that differ from those
accessible to PA produced by PLD1, which is primarily present in the Golgi and the nucleus
[69]. The PA originating from the phosphorylation of DAG by DGK may be located near
the cytoplasm, ER or nucleus, depending on the location of the specific DGK isoform [70].
Some evidence exists for these differences in function. PA that is derived from the PLD
pathway activates mTORC1 signaling and inhibits insulin signaling by enhancing IRS1
phosphorylation at serine sites [19,71], whereas PA synthesized by the GPAT–AGPAT
pathway inhibits mTORC2 signaling but has no effect on mTORC1 [28]. Another possible
explanation for these findings is that the targets of PA have different locations; the mTOR–
raptor complex that defines mTORC1 has a non-nuclear location, whereas the mTOR–rictor
complex (mTORC2) is present in both nuclear and non-nuclear locations [72].
As DAG is a hydrophobic molecule, the enzymes that catalyze its conversion to PA or TAG
must associate with membranes. In T cells, for example, DGKα redistributes between the
plasma membrane and cytosol, and developmentally in neurons, DGKζ moves between the
nucleus and cytoplasm [70]. In other cell types, DGKβ colocalizes with actin filaments,
DGKγ resides in the Golgi complex and DGKε localizes to the ER [70]. The different
subcellular locations of the DGK isoforms suggest that not all DGK isoforms play an equal
role in DAG catabolism and PA production.
Conclusion
Most of the evidence for effects of lipid intermediates on insulin signaling has been
correlative, and few studies have carefully examined the effects of a lipid species that
originates from different pathways or from different subcellular locations. DAG has been
widely accepted as causing insulin resistance in liver and muscle, but the evidence is
primarily associative. More direct evidence exists for PA and ceramide. It is likely that
many apparent discrepancies will be resolved by examining the fatty acid composition of the
PA, DAG and ceramide species that increase as insulin resistance develops. The fact that
PLD-derived PA stabilizes mTORC2, whereas GPAT1-derived PA disassociates mTORC2
strongly suggests that the two PA pools differ in some major way. It will be important to
analyze the source, composition and location of the lipid intermediates, and to learn the
precise mechanisms by which these molecules act to impair insulin signaling.
Future perspective
To fully understand the roles of lipid intermediates in the development of insulin resistance,
one must carefully identify the putative lipid species that seem physiologically plausible.
Which fatty acid composition of a lipid species is most effective? Are there functional
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differences between lipids that originate from different pathways (e.g., PA derived from
PLD, DGK or GPAT)? Does it matter where the lipid is produced or where its target effector
protein is located? Finally, what are the mechanisms involved and how do specific lipid
molecules interact with putative modulators of insulin signaling such as PKC and mTOR?
It is our belief that insulin resistance is the result of multiple modes of cellular organelle
dysfunction, including those of mitochondria and ER. In addition, aberrant signals that
originate from oxidative stress and inflammation-related cytokines may also contribute to
the development of insulin resistance. The presence of lipid intermediates may initiate or
exacerbate the development of insulin resistance if they are present either in excess, in
atypical subcellular locations or with unusual access to the nodes of the insulin-signaling
pathway.
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Obesity, lipids & insulin resistance
• It has long been observed that obese people are predisposed to have insulin
resistance, but the mechanism remains unclear. Lipid intermediates produced
within the pathways of triacylglycerol (TAG) or sphingolipid synthesis have
been associated with interrupted insulin signaling. Among these intermediates
are diacylglycerol (DAG), which activates most forms of PKC, phosphatidic
acid (PA), which alters mTOR kinase activity, and ceramides, which impair Akt
signaling.
TAG synthesis & its association with insulin resistance
• TAG itself probably does not directly inhibit insulin signaling; instead, lipid
metabolites produced during the synthesis of TAG are likely to suppress insulin
action.
Lysophosphatidic acid
• Elevated glycerol-3-phosphate acyltransferase-derived lysophosphatidic acid is
associated with hepatic insulin resistance, but it remains uncertain whether the
LPA has direct effects on insulin signaling.
Phosphatidic acid
• As a lipid messenger, PA may regulate insulin signaling via its interaction with
mTORC1 and mTORC2. Direct evidence has shown that glycerol-3-phosphate
acyltransferase-derived di-16:0 PA disrupts the association between mTOR and
rictor.
Diacylglycerol
• DAG is widely accepted as a link between lipid metabolism and insulin
resistance, due to its ability to activate conventional and novel PKC isoforms,
which inhibit insulin signaling by phosphorylating serines of IRS1. However,
some studies show an inconsistent relationship between DAG content and
insulin resistance.
Acyl-CoA & ceramide
• Although both long-chain acyl-CoAs and ceramides are believed to inhibit
insulin signaling, the data for ceramides are more robust than those for long-
chain acyl-CoAs. Additional studies are needed to verify the effects of acyl-CoA
in mediating lipid-associated insulin resistance.
Subcellular location & accessibility of lipid intermediates
• As the enzymes involved in TAG and ceramide metabolism reside in multiple
subcellular localizations, it is possible that the same lipid intermediate could
exhibit different signaling functions depending on its origin. This may be
particularly true for PA and DAG species that are produced by different
pathways.
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Figure 1. Triacylglycerol synthesis-derived lipid intermediates and insulin signaling regulation
Long-chain fatty acids enter the cell and are activated by acyl-CoA synthetases to form acyl-
CoAs, which are then esterified to glycerol-3-phosphate to form LPA by glycerol-3-
phosphate acyltransferase (GPAT). A second esterification by 1-acyl-GPAT produces PA.
The phosphate is cleaved by PA phosphohydrolase (lipin) to form DAG and a third
esterification converts the DAG to TAG. TAG is hydrolyzed by adipose TAG lipase to
produce DAG, which can be phosphorylated by DAG kinase to form PA. Acyl-CoAs can
also be converted to ceramide. Phospholipids can be hydrolyzed by PLD to form PA, LPA,
PA, DAG, acyl-CoA and ceramides, which are all signaling molecules that may interfere
with insulin signaling. PA originating from the GPAT pathway disrupts the mTOR–rictor
complex to inhibit Akt phosphorylation and propagation of the insulin signal, and PA
derived from PLD hydrolysis stabilizes mTOR/S6K1. DAG from the GPAT pathway
activates conventional and novel PKC isoforms that phosphorylate IRS1 on serine residues
and inhibit insulin signaling. LPA synthesized from the GPAT pathway may affect insulin
signaling by activating PPARγ. Acyl-CoAs may affect insulin signaling by interacting at the
IRS1/PI3K node. Ceramides may affect glucose uptake by inhibiting hexokinase or may
activate PKCθ, which disrupts insulin signaling. Dashed lines indicate that the interaction
may be indirect and have intervening nodes.
Acyl-CoA: Acyl-coenzyme A; DAG: Diacylglycerol; DGK: DAG kinase; LPA:
Lysophosphatidic acid; PA: Phosphatidic acid; PC: Phosphatidylcholine; PE:
Phosphatidylethanolamine; PLD: Phospholipase D; TAG: Triacylglycerol.
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